Our former @BIDMC_HOFellows @KartikSehgal_MD and associate fellowship director @DeepaRangachari (thoracic oncology) also have highlighted how extended-interval dosing of immune checkpoint inhibitors can be used during the pandemic https://t.co/0pK82nr7P5
Extended-Interval Dosing Strategy of Immune Checkpoint Inhibitors in Lung Cancer: Will it Outlast the COVID-19 Pandemic? ... https://t.co/jnR3jBO6mR
New research: Extended-Interval Dosing Strategy of Immune Checkpoint Inhibitors in Lung Cancer: Will it Outlast the COVID-19 Pandemic?: Patients with lung cancer are particularly vulnerable to complications from coronavirus disease-2019… https://t.co/oclHo
RT @KartikSehgal_MD: 1/8 Our review article on extended-interval dosing strategy of immune checkpoint inhibitors (ICI) now out @FrontOncolo…
RT @KartikSehgal_MD: 1/8 Our review article on extended-interval dosing strategy of immune checkpoint inhibitors (ICI) now out @FrontOncolo…
RT @KartikSehgal_MD: 1/8 Our review article on extended-interval dosing strategy of immune checkpoint inhibitors (ICI) now out @FrontOncolo…
RT @NicoleKuderer: #OncoAlert interval dosing strategy of immune checkpoint inhibitors (ICI) now out @StephenVLiu & Team summarize PK, PD…
RT @NicoleKuderer: #OncoAlert interval dosing strategy of immune checkpoint inhibitors (ICI) now out @StephenVLiu & Team summarize PK, PD…
RT @NicoleKuderer: #OncoAlert interval dosing strategy of immune checkpoint inhibitors (ICI) now out @StephenVLiu & Team summarize PK, PD…
#OncoAlert interval dosing strategy of immune checkpoint inhibitors (ICI) now out @StephenVLiu & Team summarize PK, PD & in silico evidence behind FDA. #IO #irAE #CPI
RT @KartikSehgal_MD: 1/8 Our review article on extended-interval dosing strategy of immune checkpoint inhibitors (ICI) now out @FrontOncolo…
Journal of Neoplasm# COVID-19#Pandemic#Submit#researcharticle#reviews#casereport #online submission# https://t.co/46Ork62ybH
RT @KartikSehgal_MD: 1/8 Our review article on extended-interval dosing strategy of immune checkpoint inhibitors (ICI) now out @FrontOncolo…
RT @KartikSehgal_MD: 1/8 Our review article on extended-interval dosing strategy of immune checkpoint inhibitors (ICI) now out @FrontOncolo…
RT @KartikSehgal_MD: 1/8 Our review article on extended-interval dosing strategy of immune checkpoint inhibitors (ICI) now out @FrontOncolo…
RT @KartikSehgal_MD: 1/8 Our review article on extended-interval dosing strategy of immune checkpoint inhibitors (ICI) now out @FrontOncolo…
RT @KartikSehgal_MD: 1/8 Our review article on extended-interval dosing strategy of immune checkpoint inhibitors (ICI) now out @FrontOncolo…
1/8 Our review article on extended-interval dosing strategy of immune checkpoint inhibitors (ICI) now out @FrontOncology. 🙏to @StephenVLiu for opportunity to summarize PK, PD & in silico evidence behind FDA approval of extended interval ICI. Key points
@drdgoldstein @oncology_bg @davidcnorrismd @Lymphomation @theNCI @VincentRK @vmontori @oncology_bg We have reviewed the PK data (flat exposure-response relationships for most) for immune-checkpoint inhibitors approved for lung cancer (link👇). @drdgoldstein